一个新的H_2受体阻断药──尼扎替丁治疗十二指肠溃疡病的疗效及安全性  

A NEW HISTAMINE 2-RECEPTOR ANTAGONIST-NIZATIDINE:IN THE SHORT-TERM TREATMENT OF DUODENAL ULCER DISEASE

作　　者：胡伏莲[1] 谢鹏雁[1] 刘建湘[1] 陈宝雯[1] 刘新光[1] 王化虹[1] 白歌[1] 

机构地区：[1]北京医科大学第一医院消化内科

出　　处：《中国临床药理学杂志》1995年第3期129-133,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：经内镜确诊的６９例十二指肠溃疡病病人，随机分为尼扎替丁组（３７例）和雷尼替丁组（３２例），两种药物剂量均为每晚３００ｍｇ口服，疗程４ｗｋ或８ｗｋ。尼扎替丁和雷尼替丁的溃疡愈合率４ｗｋ分别为９７．３％和９６．９％，８ｗｋ均为１００％，两组间无显著性差异（Ｐ＞０．０５）。但对疼痛的缓解，无论是治疗后３ｄ，１ｗｋ及２ｗｋ的疼痛缓解率，尼扎替丁组明显高于雷尼替丁组（Ｐ＜０．０５）。治疗中两种药物均无严重不良反应。因此，尼扎替丁是一个新的治疗十二指肠溃疡病的安全有效的Ｈ２受体阻断药。Sixty-nine patients with endoscopically proved duodenal ulcer disease were evaluated for 4-8 weeks in a randomized clinical trial,comparing nizatidine(Eli Lilly)300 mg at bed time and ranitidine(Glaxo)300mg at bed time.Endoscopy was performed after 4 weeks to assess healing,and was repeated after 8 weeks if healing had not occurred by the end of the 4 weeks.The healing rates of nizatidine and ranitidine were 97.3% and 96.9%in the 4 weeks respectively,and both 100% in 8 weeks(P>0.05).The pain relief was promt and dramatic with nizatidine treatment.48.5%,70%,86.5% of patients with nizatidine became,asymptomatic by day 3,7 and 14 respectively as compared with 21.4%,28.6%,and 64.3%of patients with ranitidine. The differences between the two groups were significant(P<0. 05)Minor adverse experiences were reported in cach treatment group.None of these experiences were serious enough to warrant discontinuation of treatment.The study has shown that nizatidine is very effective and safe for the treatment of duodenal ulcer disease.Concluson:The study had shown,(1)Nizatidine was similar in the healing rate of duodenal ulcer to ranitidine,and both were effective for treatment of duodenal ulcer disease;(2) Nizatidine was superior to ranitidine in the pain relief rate;(3)Nizatidine was generally well tilerated with few patients reporting side dffects,and no side effects were considered serious.

关 键 词：H2受体阻断药 尼扎替丁 十二指肠溃疡 药物疗法 

分 类 号：R975.6[医药卫生—药品]